$DFFN: Diffusion Pharmaceuticals Inc. - Common Stock

Diffusion Pharmaceuticals Inc. (DFFN) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases caused by protein misfolding. The company's lead product candidate, DPI-103, is a small molecule that targets the aggregation of amyloid beta (Aβ), a protein that is implicated in Alzheimer's disease. DPI-103 is currently in Phase 2 clinical trials for the treatment of Alzheimer's disease.

In addition to DPI-103, Diffusion Pharmaceuticals is also developing DPI-104, a small molecule that targets the aggregation of tau protein, another protein that is implicated in Alzheimer's disease. DPI-104 is currently in preclinical development.

Diffusion Pharmaceuticals was founded in 2013 by a team of experienced scientists and drug developers. The company is headquartered in Cambridge, Massachusetts.

Here is a more detailed description of Diffusion Pharmaceuticals' two lead product candidates:

• DPI-103: DPI-103 is a small molecule that targets the aggregation of Aβ, a protein that is implicated in Alzheimer's disease. Aβ is a naturally occurring protein that is thought to play a role in the formation of amyloid plaques, which are one of the characteristic hallmarks of Alzheimer's disease. DPI-103 works by binding to Aβ and preventing it from aggregating. In preclinical studies, DPI-103 has been shown to reduce the formation of amyloid plaques and improve cognitive function in animal models of Alzheimer's disease.
• DPI-104: DPI-104 is a small molecule that targets the aggregation of tau protein, another protein that is implicated in Alzheimer's disease. Tau is a protein that helps to stabilize microtubules, which are structures that provide support for nerve cells. In Alzheimer's disease, tau can become abnormally phosphorylated and aggregated, leading to the formation of neurofibrillary tangles, which are another characteristic hallmark of the disease. DPI-104 works by binding to tau and preventing it from aggregating. In preclinical studies, DPI-104 has been shown to reduce the formation of neurofibrillary tangles and improve cognitive function in animal models of Alzheimer's disease.

Diffusion Pharmaceuticals is currently conducting Phase 2 clinical trials of DPI-103 for the treatment of Alzheimer's disease. The company expects to report top-line results from these trials in 2023. Diffusion Pharmaceuticals is also conducting preclinical studies of DPI-104.

If successful, DPI-103 and DPI-104 could be potential new treatments for Alzheimer's disease. Alzheimer's disease is a devastating disease that affects millions of people worldwide. There are currently no effective treatments for Alzheimer's disease, and the disease is often fatal. DPI-103 and DPI-104 could provide much-needed new treatment options for people with Alzheimer's disease.

In addition to DPI-103 and DPI-104, Diffusion Pharmaceuticals is also developing a pipeline of other product candidates. These product candidates target other diseases caused by protein misfolding, such as Parkinson's disease and Huntington's disease. Diffusion Pharmaceuticals is committed to developing innovative new therapies to treat these devastating diseases.

Diffusion Pharmaceuticals is a well-funded company with a strong team of scientists and drug developers. The company has raised over $100 million in funding to date. Diffusion Pharmaceuticals is also partnered with leading pharmaceutical companies, such as Pfizer and Takeda, to develop its product candidates.

Diffusion Pharmaceuticals is a promising company with the potential to develop new treatments for Alzheimer's disease and other diseases caused by protein misfolding. The company is well-funded and has a strong team of scientists and drug developers. Diffusion Pharmaceuticals is a company to watch in the years to come.